The current price of SOPH is $7.14 — it has increased by 7.85% since the previous close. Data as of Nov 6, 2026.
SOPH is down 6.79% over the past week, down 0.14% over the past month and up 63.39% over the past year. The price is above its 200-day moving average of $5.99.
Analysts' average 12-month price target for SOPH is $11.50, which implies 61.06% upside from the current price. Individual estimates range from $9.00 to $14.00.
Of the 5 analysts covering SOPHiA GENETICS S.A., 5 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
SOPHiA GENETICS S.A. has a market capitalization of $607.81M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, SOPHiA GENETICS S.A. posted a loss of $0.24 per share against an estimate of -$0.198, missing expectations by 21.21%. Upcoming reports are listed in the earnings calendar.
SOPHiA GENETICS S.A. reported revenue of $24.27M in its most recent quarter, which has increased by 24.69% compared with the same quarter a year earlier. Analysts had expected $24.03M.
Companies most comparable to SOPHiA GENETICS S.A. include Tempus AI, Inc., BillionToOne, Inc., Certara, Inc., Personalis, Inc. and HealthStream, Inc.
In the latest trading session SOPH moved between $6.70 and $7.17, a range of 6.58% of its current price.
Over the past 52 weeks SOPH has traded between $3.83 and $8.98. The current price is 20.49% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.